CAD and AMI: Short Communication
Sankhesara D.M. · Lan N.S.R. · Gilfillan P. · Zounis E. · Rajgopal S. · Chan D.C. · Pang J. · Hillis G.S. · Watts G.F. · Schultz C.J.Background Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease. The burden of thrombus in ST-segment elevation myocardial infarction (STEMI) has implications on treatment and outcomes. However, the association between Lp(a) and atherothrombosis in STEMI remains unclear. Objectives Determine the association between Lp(a) and culprit artery thrombus burden in younger patients with STEMI. Methods Single-centre study of 83 patients aged 30 mg/dL. Multivariate analysis was performed adjusting for cardiovascular risk factors. Results The mean age was 48.08.4 years and 78.3% were male. Thirteen (16%), 9 (11%) and 61 (73%) patients had small, moderate, or large thrombus burden, respectively, and 34 (41%) had elevated Lp(a). Elevated Lp(a) was associated with greater thrombus burden compared to normal Lp(a) (large burden 85% versus 65%; P=0.024). Elevated Lp(a) was associated with moderate or large thrombus in univariate [OR 10.70 (95% CI 1.32-86.82); P=0.026] and multivariate analysis [OR 10.33 (95% CI 1.19-89.52); P=0.034]. Lp(a) was not associated with culprit artery or stenosis location according to culprit artery. Conclusions Elevated Lp(a) is associated with greater thrombus burden in younger patients with STEMI. The finding of this observational study accords with the thrombotic and anti-fibrinolytic properties of Lp(a). A causal relationship requires verification.
The Author(s). Published by S. Karger AG, Basel
Article / Publication Details Open Access License / Drug Dosage / Disclaimer This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Comments (0)